Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
111
Completed, industry sponsors, Rare and genetic disease, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed111
111 trials
Showing 1 to 25, recently updated first.
Sangamo TherapeuticsIndustry
NCT04046224 · 36 participants · Start Jul 23, 2019 · Primary completion Apr 10, 2025
Drug: ST-920 · For: Fabry Disease
Sites: Irvine, California; Tampa, Florida; Atlanta, Georgia · 18 sites in all
Nacuity Pharmaceuticals, Inc.Industry
NCT05994534 · 8 participants · Start Oct 29, 2023 · Primary completion May 26, 2026
Drug: Cysteamine Bitartrate; N-Acetylcysteine Amide · For: Cystinosis
Sites: Westmead, Australia
- First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With PhenylketonuriaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05781399 · 163 participants · Start Oct 31, 2022 · Primary completion Jul 29, 2025
Drug: JNT-517 Suspension; Placebo Suspension and 2 more · For: Phenylketonuria
Sites: Gainesville, Florida; Tampa, Florida; Atlanta, Georgia · 15 sites in all
ShireTakeda (TAK)
NCT03771898 · 36 participants · Start May 13, 2019 · Primary completion Mar 8, 2023
Drug: SHP611 · For: Metachromatic Leukodystrophy (MLD)
Sites: Torrance, California; Aurora, Colorado; Atlanta, Georgia · 30 sites in all
- A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05358717 · 159 participants · Start Jun 3, 2022 · Primary completion Feb 7, 2025
Drug: PTC518; Placebo · For: Huntington Disease
Sites: La Jolla, California; Nashville, Tennessee; Houston, Texas · 28 sites in all
Azafaros B.V.Industry
NCT05758922 · 13 participants · Start Apr 24, 2023 · Primary completion Apr 19, 2024
Drug: AZ-3102 (Dose 1); Placebo and 1 more · For: GM2 Gangliosidosis; Niemann-Pick Disease, Type C
Sites: Curitiba, Brazil; Porto Alegre, Brazil; Rio de Janeiro, Brazil
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06637514 · 14 participants · Start Jul 16, 2025 · Primary completion May 8, 2026
Drug: JNT-517 Tablet; JNT-517 Tablet · For: Phenylketonuria (PKU)
Sites: Gainesville, Florida; Tampa, Florida; Portland, Oregon · 7 sites in all
ShireTakeda (TAK)
NCT01887938 · 24 participants · Start May 23, 2013 · Primary completion Feb 13, 2026
Drug: HGT-1110 · For: Metachromatic Leukodystrophy (MLD)
Sites: Westmead, Australia; Porto Alegre, Brazil; Brno, Czechia · 15 sites in all
SanofiSanofi (SNY)
NCT06949358 · 3 participants · Start Nov 18, 2021 · Primary completion Apr 8, 2025
Drug: Olipudase alfa · For: Acid Sphingomyelinase Deficiency
Sites: Bron, France; Paris, France
- Efficacy and Safety of mAnnitol in Bowel Preparation During Elective Colonoscopy and Comparison With Moviprep®Pivotal-lookingCompleted
NTC srlIndustry
NCT04759885 · 886 participants · Start Jun 18, 2020 · Primary completion Jul 16, 2021
Drug: Phase II: NTC015 low dose; Phase II: NTC015 medium dose and 3 more · For: Elective Colonoscopy
Sites: Avignon, France; Lyon, France; Montpellier, France · 35 sites in all
Amicus TherapeuticsIndustry
NCT02675465 · 29 participants · Start Apr 2016 · Primary completion Aug 22, 2024
Drug: ATB200; AT2221 · For: Pompe Disease
Sites: Phoenix, Arizona; Orange, California; Gainesville, Florida · 19 sites in all
QED Therapeutics, a BridgeBio companyIndustry
NCT04265651 · 84 participants · Start Mar 10, 2020 · Primary completion Oct 21, 2024
Drug: Infigratinib 0.016 mg/kg; Infigratinib 0.032 mg/kg and 3 more · For: Achondroplasia
Sites: Oakland, California; Wilmington, Delaware; Baltimore, Maryland · 19 sites in all
- An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)Completed
JCR Pharmaceuticals Co., Ltd.Industry
NCT04453085 · 14 participants · Start Oct 28, 2021 · Primary completion May 2, 2025
Drug: JR-171 · For: Mucopolysaccharidosis I
Sites: Oakland, California; Porto Alegre, Brazil; São Paulo, Brazil · 6 sites in all
TakedaTakeda (TAK)
NCT01506141 · 15 participants · Start Aug 1, 2010 · Primary completion Apr 30, 2024
Drug: Idursulfase-IT; Elaprase · For: Hunter Syndrome
Sites: Chicago, Illinois; Chapel Hill, North Carolina; Portland, Oregon · 9 sites in all
JCR Pharmaceuticals Co., Ltd.Industry
NCT03359213 · 18 participants · Start Jul 26, 2018 · Primary completion Oct 4, 2019
Drug: JR-141; JR-141 and 1 more · For: Mucopolysaccharidosis II
Sites: Porto Alegre, Brazil; São Paulo, Brazil
- Drug-drug Interaction StudyCompleted
Amicus TherapeuticsIndustry
NCT01380743 · 25 participants · Start Oct 31, 2011 · Primary completion Jan 4, 2013
Drug: duvoglustat; rhGAA · For: Pompe Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Orange, California · 15 sites in all
- Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT02412787 · 56 participants · Start Apr 14, 2015 · Primary completion Apr 18, 2024
Drug: Idursulfase-IT; Elaprase · For: Hunter Syndrome
Sites: Oakland, California; Chicago, Illinois; Chapel Hill, North Carolina · 9 sites in all
JCR Pharmaceuticals Co., Ltd.Industry
NCT04227600 · 18 participants · Start Sep 1, 2020 · Primary completion Aug 2, 2022
Drug: JR-171 (lepunafusp alfa) · For: Mucopolysaccharidosis I
Sites: Oakland, California; Porto Alegre, Brazil; São Paulo, Brazil · 6 sites in all
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00517153 · 29 participants · Start Jan 2002 · Primary completion Sep 2006
Drug: miglustat · For: Niemann-Pick Type C Disease
AmgenAmgen (AMGN)
NCT00872729 · 9 participants · Start May 2009 · Primary completion Oct 2009
Drug: Cystagon®; RP103 · For: Cystinosis
Sites: San Diego, California
- Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type CPivotal-lookingCompleted
ZevraDenmarkIndustry
NCT02612129 · 50 participants · Start Jun 14, 2016 · Primary completion Jun 25, 2018
Drug: arimoclomol; Placebo · For: Niemann-Pick Disease, Type C
Sites: Oakland, California; Rochester, Minnesota; Copenhagen, Denmark · 14 sites in all
- Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase DeficiencyPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02004691 · 36 participants · Start Dec 18, 2015 · Primary completion Mar 15, 2021
Drug: placebo (saline); Olipudase alfa · For: Sphingomyelin Lipidosis
Sites: San Francisco, California; Decatur, Georgia; The Bronx, New York · 24 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02004704 · 25 participants · Start Dec 4, 2013 · Primary completion Sep 6, 2023
Drug: GZ402665 · For: Sphingomyelin Lipidosis
Sites: New York, New York; Leuven, Belgium; Porto Alegre, Brazil · 9 sites in all
IntraBio IncIndustry
NCT03759665 · 30 participants · Start Jun 7, 2019 · Primary completion Jan 9, 2023
Drug: IB1001 · For: GM2 Gangliosidosis; Tay-Sachs Disease; Sandhoff Disease
Sites: Los Angeles, California; Rochester, Minnesota; New York, New York · 8 sites in all
- Avalglucosidase Alfa Extension StudyCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02032524 · 19 participants · Start Feb 27, 2014 · Primary completion Dec 12, 2022
Drug: Avalglucosidase Alfa · For: Glycogen Storage Disease Type II Pompe Disease
Sites: Phoenix, Arizona; Jacksonville, Florida; Kansas City, Kansas · 17 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.